Unfortunately, in this article in the September 2019 issue of the European Respiratory Review, the mechanism of action for PBI-4050 in table 2 was presented incorrectly as anti-CTGF antibody. The correct mechanism of action should be GPR84 antagonist/GPR40 agonist. The article has been corrected and republished online.
- Copyright ©ERS 2019.
http://creativecommons.org/licenses/by-nc/4.0/
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Vol 28 Issue 153
Table of Contents
“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021.
